CLAIMS

What is claimed:

1. A method for obtaining a composition comprising an anti-α4β7 antibody from a liquid solution comprising the anti-α4β7 antibody and one or more impurities, said method comprising

contacting a matrix comprising Protein A with the liquid solution comprising the anti-α4β7 antibody and one or more impurities, such that the anti-α4β7 antibody binds to the Protein A;

washing the matrix comprising Protein A with a wash solution; and

eluting the anti-α4β7 antibody from the matrix comprising Protein A by contacting the matrix with an elution solution having a pH of 3.7 to 4, such that a composition comprising the anti-α4β7 antibody is obtained,

wherein the composition comprising the anti-α4β7 antibody comprises less than 1% high molecular weight (HMW) aggregates,

wherein the anti-α4β7 antibody is a vedolizumaba, and

wherein the anti-α4β7 antibody was produced in a Chinese Hamster Ovary (CHO) cell.

2. The method of claim 1, wherein the wash solution has a pH of about 7.

3. The method of claim 1 or 2, wherein the elution solution comprises citric acid.

4. The method of any one of claims 1 to 3, wherein the CHO cell is deficient in the gene encoding glutamine synthetase (GS-CHO cell).

5. The method of any one of claims 1 to 4, wherein the composition obtained comprises purified anti-α4β7 antibody, and wherein the method further comprises a subsequent step of formulating the anti-α4β7 antibody into a formulation suitable for human use.

6. The method of any one of claims 1 to 5, wherein the method comprises formulating the purified anti-α4β7 antibody into a dry, lyophilized formulation.

7. The method of any one of claims 1 to 5, wherein the method comprises formulating purified anti-α4β7 antibody into a liquid formulation so that the anti-α4β7 antibody is suitable for administration by subcutaneous injection.

8. A composition comprising an anti-α4β7 antibody, wherein said composition is obtainable by the method of any one of claims 1-7, wherein the composition comprising the anti-α4β7 antibody comprises less than 1% high molecular weight (HMW) aggregates.